Company Encyclopedia
View More
name
SYPM
301017.SZ
ShuYu Civilian Pharmacy Corp., Ltd. engages in the pharmaceutical retail chain business in China. The company is also involved in the pharmaceutical wholesale business. ShuYu Civilian Pharmacy Corp., Ltd.
90.45 B
301017.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Drug RetailIndustry
Industry Ranking7/9
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-3.06%D
    • Profit Margin-0.67%D
    • Gross Margin25.61%C
  • Growth ScoreC
    • Revenue YoY2.09%C
    • Net Profit YoY-58.23%D
    • Total Assets YoY7.85%B
    • Net Assets YoY-3.36%D
  • Cash ScoreD
    • Cash Flow Margin-14950.52%E
    • OCF YoY2.09%C
  • Operating ScoreA
    • Turnover1.03A
  • Debt ScoreE
    • Gearing Ratio77.74%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SYPM released its performance for the first three quarters, with a net profit attributable to the parent company of 109 million yuan, an increase of 927.37%

    SYPM released its third-quarter report for 2025, with operating revenue for the first three quarters at 7.446 billion yuan, a year-on-year increase of 5.19%; net profit attributable to the parent company was 109 million yuan, a year-on-year increase of 927.37%; net profit excluding non-recurring gains and losses was 9.4046 million yuan, a year-on-year increase of 160.23%; basic earnings per share were 0.27 yuan

    Zhitong·
    SZ
    301017
    +4.47%
    Zhitong·
    SZ
    301017
    +4.47%

    The pharmaceutical commercial sector experiences a surge, China Meheco hits the daily limit up

    The pharmaceutical commercial sector experienced a surge, with China Meheco hitting the daily limit, followed by Liuyao Group, SYPM, SHKK, LBX, and Hezong Medicine Easy-To-Buy Pharmaceutical rising in tandem

    Zhitong·
    SH
    600056
    +0.18%
    SZ
    301017
    +4.47%
    SH
    600272
    -5.70%
    Zhitong·
    SH
    600056
    +0.18%
    SZ
    301017
    +4.47%
    SH
    600272
    -5.70%

    SYPM released its performance for the first half of the year, with a net profit attributable to the parent company of 36.2509 million yuan, an increase of 49.83%

    SYPM released its 2025 semi-annual report, with operating revenue of 4.881 billion yuan, a year-on-year increase of 1.30%. The net profit attributable to the parent company was 36.2509 million yuan, an increase of 49.83%; the net profit excluding non-recurring gains and losses was 31.5454 million yuan, an increase of 24.63%. The basic earnings per share were 0.09 yuan

    Zhitong·
    SZ
    301017
    +4.47%
    Zhitong·
    SZ
    301017
    +4.47%

    SYPM's actual controller Li Wenjie plans to reduce his holdings by no more than 2%

    According to Zhitong Finance APP, SYPM announced that the company's controlling shareholder, actual controller, and chairman Mr. Li Wenjie plans to reduce his holdings in the company through block trades from August 28, 2025, to November 27, 2025, by no more than 8.0473 million shares, accounting for 2% of the company's total share capital

    Zhitong·
    SZ
    301017
    +4.47%
    Zhitong·
    SZ
    301017
    +4.47%

    China Post Securities: The retail pharmacy industry continues to clear out, and the ongoing coordination is expected to bring performance growth

    China Post Securities released a research report indicating that the retail pharmacy industry is accelerating its clearance, with the number of closed pharmacies reaching 39,228 in 2024. It is expected that after industry consolidation, leading pharmacies will see a recovery in customer traffic. Leading pharmacies, leveraging their first-mover advantage in outpatient management, will attract more customers, enhance medical insurance consumption and related product consumption, thereby increasing the average transaction value and performance. Policy-driven prescription outflow and the trend of incorporating retail pharmacies into medical insurance management will further promote industry development

    Zhitong·
    SH
    603233
    -0.50%
    SH
    605266
    +0.40%
    SZ
    002727
    +0.31%
    Zhitong·
    SH
    603233
    -0.50%
    SH
    605266
    +0.40%
    SZ
    002727
    +0.31%
    © 2025 Longbridge｜Disclaimer